Invizius announces ‘Angry Blood’ Haemodialysis Study and recruits its 300th patient
Novel study is investigating dysregulation of the complement system during standard hemodialysis therapy in relation to patient health outcomes
Glasgow, Scotland, 13 June 2023 – Invizius Limited (“Invizius”), a biotechnology company developing second generation therapies for a range of complement-driven autoimmune and inflammatory disorders, is pleased to announce that it has recruited its 300th patient to the ‘Angry Blood’ study. This is a significant milestone in its novel kinetic study to identify patients with elevated complement responses during haemodialysis (HD), so-called ‘angry blood,’ who may have a high risk of serious cardiovascular complications, the major cause of mortality in HD patients.
